From Pain Relief to Cancer Defense: The Promise of NSAIDs

V., Senthilnathan and V., Priyadharshini and J., Jenifer Selin Asha (2023) From Pain Relief to Cancer Defense: The Promise of NSAIDs. Journal of Advances in Medical and Pharmaceutical Sciences, 25 (9). pp. 59-67. ISSN 2394-1111

[thumbnail of Senthilnathan2592023JAMPS107198.pdf] Text
Senthilnathan2592023JAMPS107198.pdf - Published Version

Download (242kB)

Abstract

NSAIDs (Non-Steroidal Anti-inflammatory Drugs) are commonly used to treat various types of pain and inflammation. In recent decades, extensive scientific research has been conducted to examine the use of NSAIDs in the treatment and prevention of cancer. Chronic inflammation has been linked to various cancer types, suggesting that prolonged inflammation can promote genetic mutations and accelerate their accumulation within cells. The COX pathway, short for Cyclooxygenase pathway, is a critical biochemical pathway in the human body involved in the production of important signaling molecules called prostaglandins. Key factors like COX enzymes and cytokines are important in the development and progression of inflammation-induced cancer. Angiogenesis occurs during inflammation, and it plays a major role in cancer development and metastasis. NSAIDs inhibit this process, which may also contribute to their anticancer effects. This review highlights the potential of NSAIDs, particularly aspirin, ibuprofen, and celecoxib, to influence various aspects of tumor behavior. Although promising, further rigorous studies are needed to establish their clinical efficacy and safety in diverse cancer scenarios. The use of NSAIDs as adjunctive therapies along with conventional treatments presents a promising avenue for enhancing cancer management strategies.

Item Type: Article
Subjects: Lib Research Guardians > Medical Science
Depositing User: Unnamed user with email support@lib.researchguardians.com
Date Deposited: 13 Oct 2023 05:31
Last Modified: 13 Oct 2023 05:31
URI: http://journal.edit4journal.com/id/eprint/1861

Actions (login required)

View Item
View Item